Interview with Ernie Cote, CEO of Chemical Information Services
Reaxys accelerates research that supports chemical R&D purchase or synthesize decisions
Providing compound information that helps pharmaceutical and chemical companies increase their earnings is a task that requires reliable sources of data. In this interview, CEO of Chemical Information Services Ernie Cote explains why his researcher team convinced him to subscribe to Reaxys as their source of synthesis and property data.
Chemical Information Services provides critical data to facilitate synthesis-or-purchase decisions in the pharmaceutical and chemical industries. CIS researchers require reliable data about real synthesis pathways and compounds that can actually be purchased. Their work depends on quick retrieval of relevant information from granted patents and peer-reviewed journals about experimental chemistry. Prophetic compounds and calculated properties are not interesting to them.
Reaxys is one of the best tools our research team has found for chemistry research — they can use it anywhere and know that they’re getting accurate, up-to-date information. Ernie Cote, CEO of Chemical Information Services
Mr. Cote is convinced that his researchers' decision to choose Reaxys was a sound one. They demonstrated that Reaxys cuts their research time by 70%. He and his team are convinced that Reaxys delivers accurate, current and relevant information. Their business depends on them remaining up-to-date and they're satisfied that they're in good hands with Reaxys.
Reaxys cuts our research time by 70%. Ernie Cote, CEO of Chemical Information Services
Download the free case study to learn more
Elsevier R&D Solutions supporting Chemical Information Services
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium